首页> 美国卫生研究院文献>BMC Palliative Care >The Palliative Radiotherapy and Inflammation Study (PRAIS) - protocol for a longitudinal observational multicenter study on patients with cancer induced bone pain
【2h】

The Palliative Radiotherapy and Inflammation Study (PRAIS) - protocol for a longitudinal observational multicenter study on patients with cancer induced bone pain

机译:姑息放疗和炎症研究(PRAIS)-对癌症引起的骨痛患者进行纵向观察性多中心研究的方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundRadiation therapy (RT) results in pain relief for about 6 of 10 patients with cancer induced bone pain (CIBP) caused by bone metastases. The high number of non-responders, the long median time from RT to pain response and the risk of adverse effects, makes it important to determine predictors of treatment response. Clinical features such as cancer type, performance status and pain intensity, and biomarkers for osteoclast activity are proposed as predictors of response to RT. However, results are inconsistent and there is a need for better predictors of RT response. A similar argument can be stated for the development of cachexia; there are currently no predictors that can identify patients who will develop cachexia later in the cancer disease trajectory. Experimental and preclinical studies show that pain, depression and cachexia are related to inflammation. However, it is not known if inflammatory biomarkers can predict CIBP, depression or development of cachexia.
机译:背景放射治疗(RT)可减轻10例因骨转移引起的癌症诱发的骨痛(CIBP)的疼痛。大量无反应者,从RT到疼痛反应的中位时间长以及不良反应的风险,因此重要的是确定治疗反应的预测因子。临床特征如癌症类型,表现状态和疼痛强度以及破骨细胞活性的生物标志物被提议作为对RT反应的预测指标。但是,结果不一致,需要更好的RT反应预测指标。对于恶病质的发展可以说出类似的观点。目前尚无可预测在癌症病程中稍后会发展恶病质的患者的预测因子。实验和临床前研究表明,疼痛,抑郁和恶病质与炎症有关。但是,尚不清楚炎症生物标记物是否可以预测CIBP,抑郁症或恶病质的发展。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号